Vestcor Inc Alnylam Pharmaceuticals, Inc. Transaction History

Vestcor Inc

$3.17 Billion
Q3 2024

A detailed history of Vestcor Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Vestcor Inc holds 2,458 shares of ALNY stock, worth $606,634. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,458

Previous 2,038 20.61%

Holding current value

$606,634

Previous $495,000 36.57%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$233.81 - $287.01 $98,200 - $120,544	420 Added 20.61%	2,458 $676,000
Q1 2024 May 14, 2024	SELL	$146.51 - $198.2 $110,615 - $149,641	-755 Reduced 27.03%	2,038 $305,000
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $3,936 - $5,110	-26 Reduced 0.92%	2,793 $535,000
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $2,390 - $2,963	-14 Reduced 0.49%	2,819 $499,000
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $2,191 - $2,826	-12 Reduced 0.42%	2,833 $568,000
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $6,649 - $11,136	48 Added 1.72%	2,845 $569,000
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $109,100 - $153,376	906 Added 47.91%	2,797 $408,000
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $53,924 - $73,737	424 Added 28.9%	1,891 $309,000
Q4 2021 Feb 15, 2022	SELL	$159.56 - $209.29 $43,240 - $56,717	-271 Reduced 15.59%	1,467 $249,000
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $38,193 - $46,739	-225 Reduced 11.46%	1,738 $328,000
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $252,500 - $347,235	1,963 New	1,963 $333,000

Others Institutions Holding ALNY

# of Institutions

642

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.4B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestcor Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vestcor Inc with notifications on news.

Account